---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-179235"
form_type: "8-K"
ticker: "VRDN"
cik: "0001590750"
company_name: "Viridian Therapeutics, Inc.\\DE"
filed_at: "2022-06-23T23:59:59+00:00"
generated_at: "2026-06-24T23:39:15.157172+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Viridian Therapeutics appoints Carrie Melvin as COO, effective June 21, 2022

## Summary
- Carrie Melvin named COO; previously SVP Clinical Development at X4 Pharmaceuticals (Nasdaq: XFOR).
- Base salary $425K, sign-on bonus $60K, target bonus 40% of base salary.
- Receives inducement option for 210,000 shares vesting over 4 years (25% at 1-year cliff).
- Melvin brings 20+ years experience from GSK, TESARO, and Kura Oncology.
- Position is newly created; company advancing late-stage clinical development for TED programs.

## SEC filing metadata
- accession: 0001193125-22-179235
- form_type: 8-K
- ticker: VRDN
- cik: 0001590750
- company_name: Viridian Therapeutics, Inc.\DE
- filed_at: 2022-06-23T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590750/000119312522179235/0001193125-22-179235-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590750/000119312522179235/d318381d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-179235
- JSON: https://secwatch.observer/filing/0001193125-22-179235.json
- Plain text: https://secwatch.observer/filing/0001193125-22-179235.txt

## Key facts
- Executive change
  Carrie Melvin was appointed as Chief Operating Officer at Viridian Therapeutics, Inc.\DE.
  - Action: appointed
  - Role: Chief Operating Officer
  source text: On June 21, 2022, the board of directors of Viridian Therapeutics, Inc. (the “Company”) appointed Carrie Melvin as Chief Operating Officer of the Company, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1590750/000119312522179235/0001193125-22-179235-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.